The farnesoid X receptor (FXR)–fibroblast growth factor 19 (FGF19) axis is involved in maintaining glucose homeostasis and gut tight-junction (TJ) integrity. We evaluated whether individuals with prediabetes or type 2 diabetes (T2D) have altered intestinal FXR-FGF19 signaling and barrier function and whether high-glucose (HG) exposure may cause these aberrations. Moreover, we tested beneficial effects of […]
Read MoreAuthor: sugaradmin
Glucokinase Activators. A Humbling Lesson in Drug Development
In 1998, Glaser et al. (1) described a mutation in the glucokinase gene (GCK) that caused autosomal-dominant hyperinsulinism. At the time, syndromic hyperinsulinemic hypoglycemia in adults was known only to be caused by mutations affecting KATP channel function but not glucokinase. Instead, GCK mutations were known to cause maturity-onset diabetes of the young (MODY) and persistent […]
Read MoreDiabetes Spotlight: Darleen Sandoval, PhD—Understanding Metabolism Through the Gut-Brain Axis
A change in elevation can have surprising effects on the human body. Even an experienced runner, for instance, accustomed to sea level, would have great difficulty with their usual jog if they were to suddenly find themself 5,000 feet up a mountain. “It’s a stress on the body to not have enough oxygen,” Darleen Sandoval […]
Read MoreIssues and Events
Issues and Events Source link
Read MoreIncretin Receptors in the Peripheral Nervous System: Implications for Obesity Treatment and Peripheral Neuropathy
There is currently a revolution in the pharmacologic treatment of obesity and diabetes with newly available agonists of incretin receptors. The health benefits of these novel treatments include not only metabolic effects but also improvements in brain neurodegenerative conditions. Receptors for incretins have been described in the hypothalamic appetite regulatory center; however, their expression in […]
Read More2120-LB: Clinical Implementation of Polygenic Risk Scores for Cardio-Renal-Metabolic Disease—Uptake and Impact in a Large Community Health System
Introduction and Objective: Polygenic risk scores (PRS) are emerging as a novel tool for prevention and management of cardio-renal-metabolic (CRM) disease. In this study, we describe results from the first year of implementing clinical PRS testing for CRM disease in a large community health system.Methods: CLIA-certified PRS testing for type 1 diabetes, type 2 diabetes, […]
Read More2121-LB: PanKbase Integrated Single-Cell Map—A Comprehensive Atlas of Human Pancreatic Islets Unlocking Insights into Type 1 and Type 2 Diabetes
Introduction and Objective: Single-cell RNA sequencing (scRNA-seq) analysis of pancreatic islet tissues is powerful for studying Type 1 and Type 2 Diabetes (T1D and T2D). Despite many existing efforts, individual datasets are modest in size and fragmented across donors, labs and conditions, highlighting the need for a single-cell (SC) atlas that collates information from diverse […]
Read More538-P: Leadership and Change Management in Diabetes Education—Addressing Health Literacy and Health Disparities in the Diabetes Belt
Introduction and Objective: The Diabetes Belt, spanning 644 counties across 15 southern states, faces disproportionately high rates of type 2 diabetes, compounded by limited health literacy and systemic inequities. This study investigates how health educators employ leadership and behavior change theories—transformational leadership, transactional leadership, the transtheoretical model, and diffusion of innovation—to design effective interventions. The […]
Read More151-OR: Comparison of WBC SPECT/CT and MRI in Diagnosis and Treatment Response of Diabetic Foot Osteomyelitis Using Paired Biopsies as Reference Standard
Introduction and Objective: The objective of this study was to compare the performance of Tc-99m WBC SPECT/CT and MRI in subjects with suspected diabetic foot osteomyelitis (DFO) using bone biopsy as a reference standard.Methods: In total, 47 subjects with suspected DFO underwent MRI and Tc-99m WBC SPECT/CT imaging prior to bone biopsy. Subjects with soft […]
Read More1397-P: Real-World Evidence on the Legacy Effect of Early vs. Late Glycaemic Reduction and All-Cause Mortality in Newly Diagnosed Type 2 Diabetes
Introduction and Objective: While clinical trials have established legacy effects in diabetes management, real-world evidence on how historical glycaemic exposures affect survival and critical time windows is limited. We evaluated the legacy effect of glycaemic exposure on all-cause mortality among newly diagnosed type 2 diabetes (T2D).Methods: This was a retrospective cohort of 52,404 newly diagnosed […]
Read More